AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
It enables referendums and plebiscites and establishes environmental protection as a fundamental state principle. The former Hanoverian Amt Neuhaus with its parishes of Dellien, Haar, Kaarßen, Neuhaus (Elbe), Stapel, Sückau, Sumte and Tripkau as well as the villages of Neu Bleckede, Neu Wendischthun and Stiepelse in the parish of Teldau and the historic Hanoverian region in the forest district of Bohldamm in the parish of Garlitz transferred with effect from 30 June 1993 from Mecklenburg-Vorpommern to Lower Saxony (Lüneburg district). From these parishes the new municipality of Amt Neuhaus was created on 1 October 1993. In 1998 Gerhard Glogowski succeeded Gerhard Schröder who became Federal Chancellor. Because he had been linked with various scandals in his home city of Brunswick, he resigned in 1999 and was replaced by Sigmar Gabriel. From 2003 to his election as Federal President in 2010 Christian Wulff was minister president in Lower Saxony. The Osnabrücker headed a CDU-led coalition with the FDP as does his successor, David McAllister. After the elections on 20 January 2013 McAllister was deselected.
Context-sensitive half-life or context sensitive half-time is defined as the time taken for blood plasma concentration of a drug to decline by one half after an infusion designed to maintain a steady state (i.e. a constant plasma concentration) has been stopped. The "context" is the duration of infusion. When a drug which has a multicompartmental pharmacokinetic model is given by intravenous infusion it initially will distribute to the central compartment and then move out of this compartment into one or two peripheral compartments. Once this infusion is discontinued, drug continues to move into the peripheral compartments until an equilibrium is reached. At this time, the only way drug may leave plasma is by metabolism or excretion. As the plasma concentration falls, the concentration gradient of drug reverses and drug moves from peripheral compartments back into plasma, maintaining the plasma concentration of the drug, often prolonging the pharmacological effect. If an infusion has reached steady state then the context-sensitive half-life is equal to the terminal plasma half-life of the drug. Otherwise it will be shorter than the terminal elimination half-life. Remifentanil is relatively context insensitive whilst fentanyl and thiopentone are examples of drugs which have significant context-sensitive changes in their half-life. The Context-Sensitive Half-Time describes the time required for the plasma drug concentration to decline by 50% after terminating an infusion of a particular duration.
is the consumption rate of A, a reactant. This is equal to the rate expression A is involved in. The rate expression is often related to the fractional conversion both through the consumption of A and through any k changes through temperature changes that are dependent on conversion.
He is a practising barrister and jurist and teaches course on human rights at Hebrew University of Jerusalem; author of best selling book on International Law (first published in 1977; 6th edition released in 2008); also edited Title to Territory, a collection of articles on title and sovereignty in international law. His textbook is one of the key tomes used in introductory courses on international law. Shaw has appeared before the European Court of Human Rights, European Court of Justice, the UK Supreme Court, and the International Court of Justice (ICJ). Before the ICJ, he has represented countries such as the UAE, Serbia, and Cameroon. He has represented Azerbaijan, Ukraine, Ireland, and Malaysia in front of the other courts. In January 2024, he was on the four-person team representing Israel in the case brought by South Africa in the ICJ regarding accusations of genocidal acts by Israel in Gaza in the course of the Gaza war.
Sources: en.wikipedia.org
Treatment is mainly supportive (gastric lavage, activated carbon, fluid resuscitation) but includes various drugs to counter the amatoxins, including intravenous penicillin and cephalosporin derivatives, and, in cases of greater ingestion, can extend to an orthotopic liver transplant. The most reliable method to treat amanitin poisoning is through gastric lavage immediately after ingestion; however, the onset of symptoms is generally too late for this to be an option. Chemically modified silibinin, silibinin dihydrogen disuccinate disodium (trade name Legalon SIL) a solution for IV administration, is used in treatment of severe intoxications with hepatotoxic substances such as paracetamol and amanitins.
== Economics == In 2011, coronary atherosclerosis was one of the top ten most expensive conditions seen during inpatient hospitalizations in the US, with aggregate inpatient hospital costs of $10.4 billion.
== Bone structure == The skeleton is a large organ that is formed and degraded throughout life in the air-breathing vertebrates. The skeleton, often referred to as the skeletal system, is important both as a supporting structure and for maintenance of calcium, phosphate, and acid–base status in the whole organism. The functional part of bone, the bone matrix, is entirely extracellular. The bone matrix consists of protein and mineral. The protein forms the organic matrix. It is synthesized and then the mineral is added. The vast majority of the organic matrix is collagen, which provides tensile strength. The matrix is mineralized by deposition of hydroxyapatite (alternative name, hydroxylapatite). This mineral is hard, and provides compressive strength. Thus, the collagen and mineral together are a composite material with excellent tensile and compressive strength, which can bend under a strain and recover its shape without damage. This is called elastic deformation. Forces that exceed the capacity of bone to behave elastically may cause failure, typically bone fractures.
Sources: en.wikipedia.org
== Dosing == Since alpha-glucosidase inhibitors are competitive inhibitors of digestive enzymes, they must be taken at the start of main meals to have maximal effect. Their effects on blood sugar levels following meals will depend on the amount of complex carbohydrates in the meal.
Joost Hiltermann of Foreign Policy wrote that whatever little material support the Houthis may have received from Iran, the intelligence and military support by US and UK for the Saudi Arabian-led coalition exceed that by many factors. In April 2015, the United States National Security Council spokesperson Bernadette Meehan remarked that "It remains our assessment that Iran does not exert command and control over the Houthis in Yemen". Joost Hiltermann wrote that Iran does not control the Houthis' decision-making as evidenced by Houthis' flat rejection of Iran's demand not to take over Sanaa in 2015. Thomas Juneau, writing in the journal, International Affairs, states that even though Iran's support for Houthis has increased since 2014, it remains far too limited to have a significant impact in the balance of power in Yemen. The Quincy Institute for Responsible Statecraft argues that Teheran's influence over the movement has been "greatly exaggerated" by "the Saudis, their coalition partners (mainly the United Arab Emirates), and their [lobbyists] in Washington." Similarly, academics such as Marieke Brandt and Charles Schmitz have stated that the allegation that the Houthis are merely an Iranian proxy force has its roots in political narratives by Saleh, Saudi Arabia, the United States and other anti-Houthi forces. While the Houthis have praised post-Islamic Revolution Iran for its opposition to American and Israeli imperialism in the Middle East, they have also criticized Iranian political and religious doctrine, including Iran's state religion of Twelver Shi'ism.
=== Microtemplate polymerization === The addition of a monomer precursor solution and crosslinking agent to a microtemplate, or mold-type device, can initiate polymerization and the formation of nanogels. This method can be used to create nanogels in specific shapes and load them with various small molecules. Lithographic microtemplate polymerization is a similar process that uses a photoinitiator and light to trigger the formation of nanogels. Lithographic microtemplate polymerization can produce smaller nanogels on a length scale of <200 nm, which has a higher resolution compared to microtemplate polymerization that does not require a photoinitiator.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.